Podcast
MSL Talk: Tom Caravela, Tara Gonzalez
Leveraging Creativity to Break into Your First MSL Role
Summary
In this episode, Alec McCarthy shares his insights on breaking into the MSL field with a creative approach. He highlights the 70/30 rule for networking, emphasizing its importance for early-career professionals, and recounts his own journey to securing an MSL position. The discussion covers strategies for effective messaging, particularly when engaging with C-suite executives, and the value of LinkedIn Premium for MSLs. Alec also explores using publishing and scientific literature to enhance job applications, aligning work with personal values, and the significance of persistence and resilience in the job search. The episode concludes with actionable advice for aspiring MSLs.
My guest today is Alec McCarthy, Medical Science Liaison at Merz Asthetics, and we discuss how to leverage creativity to break into your first MSL role.
Alec shares…
👉 What the 70/30 rule is and what the process is about
👉 What is important for aspiring MSLs to get noticed
👉 How to approach companies that you are targeting
👉 What tools and resources to rely on during the search process
👉 Creative tips
Provide 5 keywords for SEO search separated by commas
Related Topics
You May Also Like
MSL Talk: Tom Caravela, Tara Gonzalez
Article
Doreen A. Ezeife MD, Francois Dionne PhD, Aline Fusco Fares MD, Ellen Laura Rose Cusano MD, Rouhi Fazelzad BSc, MISt, Wenzie Ng BSc, MPharm, RPh, Don Husereau BSc Pharm, MSc, Farzad Ali BPharm, MSc, Christina Sit MSc, Barry Stein B.Com BCL, LLB, Jennifer
Value assessment of oncology drugs using a weighted criterion-based approach
Article
Haiqing Isaac Dai, Yulia Vugmeyster, Naveen Mangal
Characterizing Exposure–Response Relationship for Therapeutic Monoclonal Antibodies in Immuno-Oncology and Beyond: Challenges, Perspectives, and Prospects
Article
Jakub P. Hlávka, PhD, Pei-Jung Lin, PhD, Peter J. Neumann, ScD
Outcome measures for oncology alternative payment models: practical considerations and recommendations
Article
E.M. Ray, L.A. Carey, K.E. Reeder-Hayes
Leveraging existing data to contextualize phase II clinical trial findings in oncology
Article
Sean X Zhang, MSc , Dean Fergusson, PhD , Jonathan Kimmelman, PhD